Vertex Pharmaceuticals Incorporated
VRTX
$388.25
-$6.88-1.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.39B | 11.09B | 11.02B | 10.63B | 10.34B |
| Total Other Revenue | 30.70M | 10.00M | -- | -- | -- |
| Total Revenue | 11.42B | 11.10B | 11.02B | 10.63B | 10.34B |
| Cost of Revenue | 4.38B | 4.34B | 4.13B | 4.06B | 3.92B |
| Gross Profit | 7.04B | 6.76B | 6.89B | 6.56B | 6.42B |
| SG&A Expenses | 1.54B | 1.49B | 1.43B | 1.46B | 1.35B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.79B | 6.69B | 6.43B | 6.39B | 6.14B |
| Operating Income | 4.63B | 4.41B | 4.59B | 4.24B | 4.20B |
| Income Before Tax | 4.37B | -300.20M | 248.50M | 259.60M | 214.70M |
| Income Tax Expenses | 736.40M | 688.70M | 784.10M | 739.40M | 704.60M |
| Earnings from Continuing Operations | 3.64K | -988.90 | -535.60 | -479.80 | -489.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.64B | -988.90M | -535.60M | -479.80M | -489.90M |
| EBIT | 4.63B | 4.41B | 4.59B | 4.24B | 4.20B |
| EBITDA | 4.80B | 4.58B | 4.77B | 4.45B | 4.39B |
| EPS Basic | 14.14 | -3.81 | -2.07 | -1.85 | -1.89 |
| Normalized Basic EPS | 12.34 | 11.82 | 12.32 | 11.58 | 11.59 |
| EPS Diluted | 13.99 | -3.92 | -2.20 | -2.00 | -2.04 |
| Normalized Diluted EPS | 12.21 | 11.72 | 12.21 | 11.48 | 11.49 |
| Average Basic Shares Outstanding | 1.03B | 1.03B | 1.03B | 1.03B | 1.03B |
| Average Diluted Shares Outstanding | 1.04B | 1.04B | 1.04B | 1.04B | 1.04B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |